A @ @ factorial design was used to test two hypotheses : ( @ ) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every @ weeks and ( @ ) that paclitaxel once per week was superior to six cycles of paclitaxel once every @ weeks in patients with node-positive or high-risk node-negative early-stage breast cancer .